| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-047 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 三、对公司的影响 心启™为治疗包括慢性完全闭塞病变（CTO）在内的冠状动脉复杂病变提供了一款 全新的优选器械。同时，作为公司旗下冠脉介入领域复杂病变器械组合中的一块重要 拼图，心启™的获批上市标志着公司冠脉介入整体解决方案战略布局的进一步落地。 1 近日，蓝帆医疗股份有限公司（以下简称"公司"）接到通知，公司心脑血管事业 部的子公司上海蓝帆博元医疗科技有限公司研发和生产的三类医疗器械产品"心启™ 冠状动脉球囊扩张导管"（以下简称"心启™"）获得国家药品监督管理局（NMPA）的 批准注册，现将相关情况公告如下： 一、获批产品基本信息 关于子公司心启™冠状动脉球囊扩张导管获得 产品名称：心启™冠状动脉球囊扩张导管 注册人名称：上海蓝帆博元医疗科技有限公司 注册证号：国械注准20243030845 中国 NMPA 注册的公告 二、产品情况介绍 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-046 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 蓝帆医疗股份有限公司（以下简称"公司"）于2024年2月21日召开第六届董事会 第七次会议、2024年3月11日召开2024年第一次临时股东大会，审议通过了《关于回购 公司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购部分公司发行 的人民币普通股（A股）股票，用于维护公司价值及股东权益所必需。 公司拟用于回购的资金总额不低于人民币2,500万元（含本数）且不超过人民币5,000 万元（含本数），回购价格不超过人民币8.60元/股（含本数），具体回购资金总额以回购 结束时实际回购使用的资金总额为准，回购股份实施期限为自公司股东大会审议通过 本次回购股份方案之日起不超过3个月。回购方案具体内容详见公司于2024年3月12日 披露在《中国证券报》、《上海证券报》、《证券时 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202402 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 ■其他（电话会议） 兴业证券、中信建投、信达证券、国盛证券、国金证券、西南证 券、开源证券、国信证券、国泰君安证券、华安证券、长江养老、 劲邦资本、博道基金、杭州兆石投资、惠升基金、开思基金、南 参与单位名称及 方基金、山高国际资管、磐耀资产、同犇投资、尚石投资、君茂 人员姓名 资本、苏州龙远投资、新思哲投资、阳光资产等机构的30名投资 者。 时间 2024年4 月28 日17:00-18:10 地点 电话会议 董事、总裁 钟舒乔先生 董事 于苏华先生 上市公司接待人 副总裁、首席财务官 崔运涛先生 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥4.93 billion, representing a slight increase of 0.54% compared to ¥4.90 billion in 2022[16]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥568.36 million, a decrease of 52.66% from a loss of ¥372.32 million in the previous year[16]. - The net cash flow from operating activities was negative at approximately ¥72.89 million, a significant decline of 114.74% compared to a positive cash flow of ¥494.47 million in 2022[16]. - The basic earnings per share for 2023 was -¥0.56, down 51.35% from -¥0.37 in 2022[16]. - Total assets at the end of 2023 were approximately ¥15.63 billion, a decrease of 1.51% from ¥15.87 billion at the end of 2022[16]. - The net assets attributable to shareholders of the listed company decreased by 9.51% to approximately ¥9.55 billion from ¥10.55 billion in 2022[16]. - The company reported a decrease in the weighted average return on net assets to -5.66% in 2023 from -3.53% in 2022[16]. - The company faced uncertainty regarding its ability to continue as a going concern, as indicated by the audit report[16]. Revenue and Market Growth - The revenue from sales of materials and rental income was approximately ¥69.44 million in 2023, compared to ¥51.85 million in 2022[17]. - The cardiovascular intervention device market is projected to grow from ¥80.17 billion in 2023 to ¥137.7 billion by 2030, with a CAGR of 7.8%[28]. - The number of PCI cases in mainland China reached 1,636,055 in 2023, marking a growth rate of 26.44% compared to the previous year[29]. - The domestic TAVR procedure volume is expected to reach approximately 15,000 cases in 2023, representing a nearly 80% increase year-on-year[31]. - The cardiovascular division reported a sales revenue of approximately 1 billion yuan in 2023, with a growth rate of about 30% compared to 2022[79]. - Sales revenue in the Chinese market grew by over 90% year-on-year, accounting for more than 30% of total revenue[79]. - The overseas sales revenue increased by over 10% year-on-year, with the Asia-Pacific region achieving nearly 20% growth[79]. Product Development and Innovation - The company has established a multi-segment strategy, focusing on high, medium, and low-value medical consumables, including cardiovascular and protective products[28]. - The cardiovascular division's flagship product, BioFreedom®, saw a domestic implantation increase of over 120% in 2023 compared to 2022, indicating strong market acceptance[41]. - The company’s new product, the BA9™ drug-coated balloon, achieved sales of over 20,000 units in China in 2023, providing a safer treatment option for coronary artery small vessel disease[42]. - The company is focused on continuous innovation in product development, particularly in the health protection sector, to meet evolving market demands[64]. - The company is actively pursuing market expansion through the introduction of innovative products in the emergency care and health protection sectors[55]. - The company has developed a series of emergency kits tailored for different environments, such as home care, outdoor activities, and office settings, to meet diverse consumer needs[55]. - The company is expanding into minimally invasive surgery, launching innovative products like the RenoVue®/RenoPort® endoscopic cleaning device[160]. Research and Development - The company invested approximately 20% of its revenue in R&D, focusing on new generation medical devices[80]. - Research and development expenses for 2023 amounted to approximately 290.75 million CNY, a decrease of 17.51% from the previous year[115]. - The company’s R&D personnel increased by 35.74% to 828 individuals, with a higher proportion of staff holding master's degrees[117][118]. - The company has established a global 24-hour R&D mechanism, with nearly 600 patents, facilitating the localization and internationalization of R&D capabilities[94]. - The company is enhancing its R&D capabilities through collaboration with universities and participation in clinical trials[186]. Strategic Partnerships and Market Expansion - The company has established strategic partnerships with major automotive manufacturers, including Tesla and Mercedes-Benz, for the supply of vehicle-mounted emergency kits[46]. - The company signed a strategic agreement with China Medical Device Co., Ltd. on November 28, 2023, to enhance industrial synergy and investment in the health and new medical fields[152]. - The company aims to align with the "Belt and Road" initiative and BRICS countries to build local industrial chains and export technology, standards, and brands[152]. - The company is expanding its global presence by integrating with local industries in overseas markets, particularly in the health sector[185]. Operational Efficiency and Cost Management - The company is enhancing cost control measures across its divisions, focusing on optimizing production efficiency and reducing production costs[166]. - The company has implemented the "Quality and Return Double Improvement" action plan to enhance investor confidence and promote sustainable development[180]. - The company is committed to compliance and quality management in response to industry policy changes and potential risks in the medical device sector[169]. - The company is enhancing its environmental governance in response to stricter national policies, which may increase operational costs[173]. Investor Relations and Governance - The company conducted over 10 investor meetings in 2023, engaging more than 230 investors to discuss its development plans and operational performance[198]. - The company is committed to improving information disclosure quality and enhancing investor communication to boost market confidence[199]. - The company will continue to refine its corporate governance structure and internal control systems to protect shareholder rights[194]. - The company is dedicated to complying with regulatory requirements and ensuring the accuracy of its financial information[197].

Financial Performance - The company's revenue for Q1 2024 reached ¥1,454,848,751.06, representing a 32.96% increase compared to ¥1,094,194,474.12 in the same period last year[6] - The net loss attributable to shareholders was ¥98,919,578.18, a 27.97% increase from a loss of ¥77,299,820.11 in the previous year[6] - Total operating revenue for Q1 2024 reached ¥1,454,848,751.06, an increase of 33% compared to ¥1,094,194,474.12 in the same period last year[29] - The company's net profit margin decreased, with a net loss from investments amounting to ¥4,316,708.96 compared to a profit of ¥6,827,686.29 in the previous year[29] - The net profit for the first quarter of 2024 was -98,738,936.80 CNY, compared to -77,299,820.11 CNY in the same period last year, reflecting an increase in net loss of approximately 27.7%[31] - Operating profit for the first quarter was -120,402,309.66 CNY, compared to -97,728,247.72 CNY in the previous year, indicating a decline of about 23.1%[31] - Total comprehensive income for the first quarter was -73,856,120.00 CNY, compared to -138,512,468.55 CNY in the same period last year, showing an improvement of approximately 46.4%[32] Revenue Breakdown - The cardiovascular division achieved sales revenue exceeding ¥290 million in Q1 2024, marking a growth of approximately 10% year-over-year[10] - The sales revenue of valve products increased by about 117% year-over-year, with both European and Asia-Pacific regions experiencing over 100% growth[10] - The protective equipment division's revenue grew nearly 44% year-over-year, driven by a nearly 40% increase in glove product sales volume[11] - The nursing division reported cumulative revenue of nearly ¥48 million in Q1 2024, with a net profit of approximately ¥4.9 million[12] - Operating revenue for the current period was ¥1,454,848,751.06, an increase of ¥360,654,276.94 or 32.96% year-on-year, primarily driven by increased sales of health protection products[15] Cash Flow and Liquidity - The company’s net cash flow from operating activities was -¥44,513,639.94, a 39.45% decline compared to -¥31,920,809.05 in the previous year[6] - Cash and cash equivalents increased by ¥660,429,886.51, a growth of 51.50% compared to the beginning of the period, mainly due to capital received by the cardiovascular division[14] - The net increase in cash and cash equivalents was ¥666,855,328.49, reflecting a growth of 243.13% compared to the previous year, primarily due to increased cash flow from financing activities[18] - Cash flow from operating activities showed a net outflow of -44,513,639.94 CNY, worsening from -31,920,809.05 CNY year-over-year[33] - Cash flow from investing activities resulted in a net outflow of -304,869,127.06 CNY, compared to -280,068,693.09 CNY in the previous year, indicating a decline of about 8.9%[34] - Cash flow from financing activities generated a net inflow of 999,420,537.31 CNY, a significant increase from -148,682,854.46 CNY in the same period last year[34] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥16,497,457,934.84, reflecting a 5.53% increase from ¥15,633,248,932.86 at the end of the previous year[6] - Current assets increased to ¥4,677,974,656.38 from ¥3,769,548,922.67, reflecting a growth of approximately 24%[26] - Non-current assets totaled ¥11,819,483,278.46, slightly down from ¥11,863,700,010.19, indicating a decrease of about 0.37%[27] - Total liabilities rose to ¥7,026,620,551.37, an increase of 15.5% from ¥6,084,894,349.53 in the previous period[28] - Long-term payables rose by ¥954,301,841.98, a significant increase of 517.65%, attributed to capital received by the cardiovascular division recognized as financial liabilities[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,948[20] - The largest shareholder, Zibo Lanfan Investment Co., Ltd., holds 30,003,077 shares, representing a significant portion of the company's equity[21] - The second-largest shareholder, Li Biao, controls 13,967,112 shares through Zhongxuan Investment Co., Ltd.[21] - The company reported a total of 10 major shareholders, with the top three holding a combined total of 55,320,189 shares[21] - The company is actively engaged in share repurchase activities, with multiple announcements regarding the repurchase plan made between February 22 and March 18, 2024[23][24] Strategic Initiatives - The company has disclosed plans for a capital increase and introduction of strategic investors for its wholly-owned subsidiary, with announcements made on January 26 and March 12, 2024[22][23] - The company is exploring market expansion strategies, as indicated by the ongoing discussions about capital increases and strategic investments[22] - The company has not disclosed any significant changes in the shareholding structure of the top 10 shareholders due to margin trading activities[21] Research and Development - Research and development expenses for Q1 2024 were ¥83,148,650.16, up from ¥71,330,456.77 in Q1 2023, reflecting a growth of approximately 16.6%[29] - There are no new product launches or technological developments mentioned in the current report[23] Other Financial Metrics - The company reported a significant increase in operating expenses, with credit impairment losses rising by ¥5,265,680.07 or 1519.30% year-on-year[15] - The basic and diluted earnings per share for the first quarter were both -0.10 CNY, compared to -0.08 CNY in the previous year[32] - The company recorded a foreign exchange gain of 16,817,558.18 CNY during the quarter, compared to a loss of -5,231,338.30 CNY in the previous year[34]

2023年度内部控制自我评价报告 蓝帆医疗股份有限公司 2023年度内部控制自我评价报告 蓝帆医疗股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简 称"企业内部控制规范体系"），结合蓝帆医疗股份有限公司（以下简称"公司"或 "本公司"）内部控制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们 对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控 制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董 事、监事、高级管理人员保证本报告内容不存在虚假记载、误导性陈述或重大遗漏，并 对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信 息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限 性，故仅能为实现上述目标提供合理保证。此外，由于 ...

证券代码：002382 证券简称：蓝帆医疗 公告编号：2024-042 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第九次会议审议通过， 公司决定于2024年5月20日召开2023年年度股东大会，现将有关事项通知如下： 一、召开会议基本情况 1、股东大会届次：2023 年年度股东大会 2、股东大会的召集人：公司第六届董事会 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： （1）现场会议时间：2024 年 5 月 20 日（星期一）下午 14：30 （2）网络投票时间：2024 年 5 月 20 日 通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时间为 2024 年 5 月 20 日上午 9：15 至 9：25，9：30 至 11：30 和下午 13：00 至 15：00； 通过深交所互 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-037 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司（以下简称"公司"） 第六届监事会第七次会议于 2024 年 4 月 12 日以电子邮件的方式发出通知，于 2024 年 4 月 25 日在公司总部第二会议 室以现场及通讯表决相结合的方式召开。本次会议应参加监事 3 人，实际参加监事 3 人，周治卫先生以现场的方式出席会议，卢凌威先生和宗秋月女士以通讯的方式出席 会议。卢凌威先生主持了本次会议。会议的召开符合《中华人民共和国公司法》和 《蓝帆医疗股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 1、审议并通过了《关于<2023 年度监事会报告>的议案》； 2023 年度，公司监事会严格按照《中华人民共和国公司法》、《中华人民共和国证 券法》等法律、法规及《公司章程》、《监事会议事规则》等部门规章、规范性文件的 规定，从切实维护公司利益和全体股东的权益特别是广大中小股东权益出发，认真履 行监督职责。 表决结果：同意票 3 票， ...

本资产评估报告依据中国资产评估准则编制 蓝帆医疗股份有限公司拟进行商誉减值测试涉及的武汉必凯尔救助用 品有限公司包含商誉资产组可收回金额 资产评估报告 格律沪评报字（2024）第 053 号 共一册第一册 格律（上海）资产评估有限公司 GeLv（Shanghai）AssetsAppraisalCo.,Ltd 2024 年 4 月 25 日 | 目录 | | --- | | 声明 1 | | --- | | 资产评估报告摘要 2 | | 资产评估报告正文 4 | | 一、委托人及其他资产评估报告使用人 4 | | 二、评估目的 8 | | 三、评估对象和评估范围 8 | | 四、价值类型及其定义 21 | | 五、评估基准日 21 | | 六、评估依据 21 | | 七、评估方法 23 | | 八、评估程序实施过程和情况 29 | | 九、评估假设 30 | | 十、评估结论 31 | | 十一、特别事项说明 32 | | 十二、资产评估报告使用限制说明 33 | | 十三、资产评估报告日 34 | | 十四、资产评估专业人员签名和资产评估机构印章 35 | | 资产评估报告附件 36 | 蓝帆医疗股份有限公司 ...

2023 年度董事会报告 蓝帆医疗股份有限公司 2023 年度董事会报告 2023 年，蓝帆医疗股份有限公司（以下简称"公司"或"蓝帆医疗"）董事会严 格按照《中华人民共和国公司法》（以下简称"《公司法》"）、和《蓝帆医疗股份有 限公司章程》（以下简称"《公司章程》"）、《董事会议事规则》等相关规定，切实 履行股东大会赋予的董事会职责，进一步规范、优化了公司法人治理结构，确保了董事 会科学决策和规范运作。在全体股东的支持下，公司董事会带领管理层和全体员工，积 极应对复杂的经营环境，促进公司持续、稳定、健康的发展。现将董事会 2023 年度工 作情况汇报如下： 一、2023 年度公司经营情况回顾 自2013年，公司确立了 "A+X"发展战略，依靠内生和外延并重的发展路径，持 续布局了精心挑选的"高、中、低值"多个医疗器械耗材赛道，产品涵盖冠脉、瓣膜、 健康防护手套、急救包等多条赛道。经过近10年的转型升级，"A+X"战略基本落地， 公司构建起了国际化、科技创新、平台化的核心优势，拥有了面向未来的创新驱动高质 量发展格局，已发展成为"以中国为核心、面向全球的跨国医疗器械综合平台型企业"， 始终坚持以科技创新驱动高 ...